Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy

Cristina Teixidó, Niki Karachaliou, Maria González-Cao, Daniela Morales-Espinosa, Rafael Rosell,,3

1Pangaea Biotech, Quirón Dexeus University Hospital, Barcelona 08028, Spain; 2Dr.Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona 08028, Spain; 3Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology,Hospital Germans Trias i Pujol, Badalona 08916, Spain

In the published article1, one error appeared on page 89.

Pembrolizumab has not yet received FDA approval for NSCLC patients.In October 2014 pembrolizumab received FDA breakthrough therapy designation for lung cancer treatment supported by data from a phase Ib trial in previously treated NSCLC patients2.

The authors apologize for the errors and for any confusion it may have caused.

Acknowledgements

We are thankful to Dr.Dickran Kazandjian from FDA/Office of Hematology and Oncology Products for pointing out this mistake.

1.Teixidó C, Karachaliou N, González-Cao M, Morales-Espinosa D,Rosell R.Assays for predicting and monitoring responses to lung cancer immunotherapy.Cancer Biol Med 2015;12:87-95.

2.Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al.Pembrolizumab for the treatment of non-small-cell lung cancer.N Engl J Med 2015;372:2018-2028.